Dannielle D. Engle

Salk Institute for Biological Studies — United States

Medicine · Health Sciences

22h-index11.5kcitations154works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pancreatic and Hepatic Oncology Research(120), Cancer Cells and Metastasis(32), Single-cell and spatial transcriptomics(19), Biochemical and Molecular Research(17), Cancer, Hypoxia, and Metabolism(15)

Publications154 total

Abstract B092: Investigating combination therapies to overcome RAS inhibitor resistance in pancreatic cancer
Cancer Research·2025
Abstract A104: The CA19-9 glycan is a viable target for CAR T cell therapy in PDAC
Cancer Research·2025
Abstract B009: Fibulin-3 drives tumor progression and microenvironment remodeling in CA19-9-induced pancreatic ductal adenocarcinoma
Cancer Research·2025
Antithrombin-binding heparan sulfate is ubiquitously expressed in epithelial cells and suppresses pancreatic tumorigenesis
Journal of Clinical Investigation·2025· 1 citedOpen Access
Experimental models of pancreas cancer: what has been the impact for precision medicine?
Journal of Clinical Investigation·2025· 4 citedOpen Access
Leveraging autophagy and pyrimidine metabolism to target pancreatic cancer
2025Open Access
Differential Effects of Confinement on the Dynamics of Normal and Tumor-Derived Pancreatic Ductal Organoids
ACS Applied Bio Materials·2024· 1 citedOpen Access
Chronic pancreatitis patient-derived organoids reveal new paths to precision therapeutics
2024Open Access
Table S2 from Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma
2024Open Access
Table S1 from Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma
2024Open Access
Table S2 from Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma
2024Open Access
Table S1 from Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma
2024Open Access
Table S3 from Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma
2024Open Access
Table S3 from Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma
2024Open Access
Supplemental Figures from Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma
2024Open Access
Supplemental Figures from Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma
2024Open Access
Data from Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma
2024Open Access
Supplementary Data from Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma
2024Open Access
Supplementary Data from Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma
2024Open Access
Abstract 1600: Interception of pro-tumorigenic glycan signaling in pancreatic cancer
Cancer Research·2024
page 1 of 8Next →

Frequent Co-authors

David A. Tuveson(27), Hervé Tiriac(19), Kenneth H. Yu(12), Youngkyu Park(11), Giulia Biffi(9), Ela Elyada(9), Matthew S. Lucito(8), Richard A. Burkhart(7), Andrew M. Lowy(7), Tobiloba E. Oni(6), Mohan Bolisetty(6), Pasquale Laise(6), William F. Flynn(6), Elise T. Courtois(6), Jonathan A. Teinor(6), Santhosh Sivajothi(6), Todd D. Armstrong(6), Christopher L. Wolfgang(6), Jonathan Preall(6), Elizabeth M. Jaffee(6)